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Abstract 
Background: The present study was formulated in order to determine pol-
ymorphism of dihydropteroate synthetase gene (dhps) of Plasmodium vivax (P. 
vivax) in Hormozgan Province, southern Iran and mutations at codons 382, 
383, 512, 553, and 585 associated with resistance of P. vivax to sulfadoxine.  
Method: One-hundred eighteen isolates of P. vivax were prepared within 
2007-2008 to determine dihydrofolate reductase-thymidylate synthase (dhfr-ts) 
gene. The isolates were determined in the study of genetic diversity of dihy-
dropteroate synthetase gene (dhps) of P. vivax. The study was performed via 
PCR test and nucleotide sequencing. 
Results: Of 118 blood samples infected by P. vivax, 46 and 72 samples be-
longed to Minab and Jask, respectively. No mutation was detected at 5 target 
codons. However, among these 118 samples, three isolates (2.54%) were 
found to have a mutation at the new codon 421. 
Conclusion: Since mutation was detected in dihydrofolate reductase (Pvdhfr) 
gene in the same samples but no mutation was found at five main codons of 
Pvdhps gene, it can be concluded that P. vivax, considering their mutations in 
Pvdhfr, is still susceptible to sulfadoxine and therefore, to fansidar in Hor-
mozgan Province, Southern Iran. 
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Introduction 
 
lasmodium vivax is claimed to infect 
around 100 million people every year 
threatening 40% of the world’s popu-
lation (1). Plasmodium falciparum and P. vivax are 
among the most important parasites transited 
by arthropods, and distributed all around the 
world (2). Because of prosperous execution of 
half-a-century preventive and controlling pro-
grams, no malaria transition has been reported 
in Iran except for some limited regions mostly 
located in the southeast (3). P. vivax is the pre-
dominant malaria parasite in Iran and Hor-
mozgan is considered one of the three endem-
ic provinces of Iran in terms of infection by 
malaria (3, 4).  
Researches on antimalarial drugs have been 
majorly focused on P. falciparum; however, 
fast-developing resistance to chloroquine in P. 
vivax has convinced authors to pay more at-
tention to the necessity of replacing antimalar-
ial drugs in vivax malaria (5). In general, it 
seems that drug resistance occurs due to mu-
tation in a specific point in one or more nu-
cleotide(s) leading to reduced susceptibility to 
some drugs or a class of drugs (6). Determina-
tion of susceptibility of P. vivax to antimalarial 
drugs is cumbersome, if not impossible, 
through lab tests (7, 8). Molecular genetic 
markers of resistance are beneficial to monitor 
the development and spread of anti-malarial 
drug resistance.  
It is necessary to gain knowledge about the 
mechanisms of drug action and resistance in 
order to eradicate malaria (9). Pyrimethamine 
and sulfadoxine are among the most widely 
used antimalarial drugs that effect on folate 
synthesis pathway (10). By interruption in fo-
late synthesis pathway caused by antifolates, 
glycine-to-serine change as well as reduced 
methionine synthesis decrease leading to 
plunge in thymidylate and DNA replication 
(10,11). Resistance to antimalarial drugs has 
been recognized for P. falciparum and P. vivax, 
which naturally infest humans. It is notewor-
thy that P. falciparium has an increasing re-
sistance to approximately all antimalarial drugs 
used extensively at the present (12). Resistance 
to fansidar occurs through a mutation in a 
specific point in dihydrofolate reductase 
(Pvdhfr) and dihydropteroate synthetase (dhps) 
genes that result in resistance to pyrimetham-
ine and sulfadoxine, respectively.  
Five codons 382, 383, 512, 553, and 585 in 
dihydropteroate synthetase (dhps) gene of P. 
vivax (Pvdhps) are associated with resistance of 
the parasite to sulfadoxine. Mutation in the 
gene and mutation outbreak in the codons 383 
and 553 leads to higher resistance levels (13, 
14).  
The present study aimed at determination of 
existence of the codons related to resistance in 
dihydropteroate synthetase gene in P. vivax 
samples in Hormozgan Province, southern Iran. 
 
Materials and Methods 
 
One-hundred eighteen positive sample of 
malaria were collected from patients suffered 
from malaria complications, from health cen-
ters of Minab and Jask from 2007 to 2008 (15, 
16). The samples were kept at -20˚C in De-
partment of Parasitology and Mycology of 
Shahid Beheshti University of Medical Scienc-
es, Tehran, Iran. Dihydropteroate synthetase 
gene positive blood samples of P. vivax were 
taken in EDTA-containing tubes was deter-
mined in those samples.  
DNG plus kit (Sinagene Corp.) was adopted 
for extraction of DNA from P. vivax. Accord-
ing to the protocol proposed by the corpora-
tion, 100 µl blood sample and 700 µl DNG 
solution were mixed and DNA was extracted. 
DNA estimation was performed via ultraviolet 
spectroscopy and electrophoresis gel.  
For PCR, a primer pair called VDHPS-OF 
and VDHPS-OR with sequences of (5'- AT-
TCCAGAGTATAAGCACAG-
CACATTTGAG-3') and (5'- CTAAGGTT-
GATGTATCCTTGTGAGCACATC-3') was 
P 
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used in order to replicate the section 1354bp 
of pyruvate kinase dihydrofolate synthase P. 
vivax pppk-dhps, respectively by using an availa-
ble gene sequence in GenBank: AY186730. A 
705-nucleotide section was replicated by use 
of a pair of primers for Nested-PCR called 
VDHPS-NF and VDHPS-NR with sequences 
of (5'-AATGGCAAGTGATGGGGCGAGCGTGA-
TTGA-3') and (5'- CAGTCTGCACTCCCCGATG-
GCCGCGCCACC-3'), respectively.  
PCR was performed by means of PreMix kit 
(INTRON Biotechnology; Cat.No: 25026, 96) 
in 30 cycles at annealing temperatures of 58 ˚C 
and 65 ˚C for external and internal sections, 
respectively. Bands of the replicated section 
after PCR were observed on electrophoresis 
gel 1.5% by trans-illuminator through ethidi-
um bromide staining and electrophoresis on 
agarosegel. The nested PCR products of pvdhps 
from the samples were subjected to direct se-
quencing in both directions by a DNA-
sequencer in Digestive Disease Research Insti-
tute and compared with the samples available 
in Gen Bank in order to determine possible 
mutations.  
 
Results 
  
Of 118 samples infested by P. vivax in Minab 
and Jask in Hormozgan Province, 46 and 72 
samples belonged to Minab and Jask, respec-
tively. Seventy-nine patients (67%) were male. 
The average age was 22 yr and the subjects 
were mostly Iranians (91.5%). Nested-PCR 
products of nine samples were shown in (Fig. 
1) with 705 nucleotides. All isolates showed 
identical bands to the ones in (Fig. 1).  
 
 
 
Fig. 1: Electrophoresis image of bp705 section of Pvdhps gene with nine isolates of P. vivax in Hormozgan 
Province 
M: 100bp DNA Ladder Numbers: The isolated numbers PC: Positive Control NC: Negative Control 
 
PCR products derived from all samples and 
705-nucleotide sections were sequenced. No 
mutations were detected by PCR and sequenc-
ing in the samples. However, among 118 sam-
ples, three isolates (2.54%) had an as-yet-
unreported mutation in the new codon 421 
(Table 1). The isolates were on the same posi-
tion and had only one mutation. A difference 
in codon 421 was first detected in the present 
study between the sequence of three isolates 
obtained from P. vivax and nucleotide se-
quence of the gens in GenBank (Fig. 2). Se-
quence of this codon was in the non-mutant 
isolate GTG where mutant turned into GAG. 
Because of this mutation, valine is turned into 
glutamic acid. Sequence of Minab and Jask 
samples were registered in GenBank bearing 
no. AB609599 and AB609600, respectively. 
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1411 aatggcaagtgatggggcgagcgtgattgacatcgggggggaatcgtccgccccttatgtggtccccaatccgagcgtcactgaacgggatttggtca-
tgcctgttttgaagctctttaaggaggagtggcataagttggagtgtgaggttggcggtggtgccgagtgctgcgctgcagcaagtgatgccaggaaaaacgcgcag-
agctccctacaggggaaactacaaaaagtgagggacgcaaaaccgatcataagcatcgacacggtcaattatgatctcttcaaggagtgcgtggaaggcgagttgg-
tggacatcctaaacgatatcagcgcgtgcacgcacaacccagagattataaaattgttgaggaggaaaaacaagttctatagcgtcgttttaatgcacaagagggg-
aaatccacacaccatggataagttaacaaattacgatgaccttataagtgacattaaaaggtatttagaagatcggctacattttctcgttctaaatggggtaccacgct-
accgagttctctttgatgtcggcctggggtttgccaaaaagcacgaccagtctattaagctgttgcagcatattcacgtttacgatgagtacccgctgtttcttggcta-
ctcgaggaagcgctttattgtcca 
2101ctgcatggggaagggtggcgcggccatcggggagtgcagactg 
 
Fig. 2: Schematic representation and nucleotide sequences of 705 bp product of the semi-nested PCR of the 
Pvdhps gene. The primer’s VDHPS-NF and VDHPS-NR annealing sites were underlined.Bold and underlined 
letters indicate Codon 421 where mutation occurred 
 
Table 1: Characteristics of isolates of mutant in the codon 421 from Hormozgan Province in dihydropteroate 
synthetase gene 
 
Isolate code Nationality Patient’s 
hometown 
Gender Age 
(yr) 
History of trip to Af-
ghanistan or Pakistan 
ShH(PV)17M-IR* Iranian Minab Male 9 No 
ShH(PV)54J-IR Iranian Jask Male 20 No 
ShH(PV)70J-IR Iranian Around Jask Female 14 No 
* Sh:Sharifi, H:Haghighi, Pv:Plasmodium vivax, M:Minab, J:Jask, Numbers: The isolated numbers, IR: Iran 
 
Discussion  
 
Resistance to chloroquine in P. vivax in some 
malaria-prone areas of the world has necessi-
tated replacing antimalarial drugs in the case 
of vivax malaria (6). Drug resistance to chloro-
quine in  P. falciparum was reported many years 
ago in Iran and therefore, Anopheles mosquitos 
have transmitted resistant parasites to all ma-
laria-prone regions (17). Despite the fact that 
sulfadoxine is not used in Iran for treating vi-
vax malaria(11), detection of mutation in dihy-
dropteroate synthetase gene in P. vivax in 
Chabahar and regions around it indicates that 
P. vivax is by any way exposed to sulfadoxine 
in southeast of Iran(unpublished data). 
In the present study, no mutation was de-
tected in 118 isolates of P. vivax in isolates ac-
quired from Minab and Jask; however, three 
mutant isolates in the new codon 421 were 
seen in Pvdhps gene, which may account for 
onset of mutation in this gene and possibly 
known codons in this region. Rudimentary 
investigations in 1959 pointed to inherent re-
sistance of P. vivax to fansidar (18). At that 
time, with advent of chloroquine-resistant 
strains of P. falciparum, antifolate drugs such 
as proguanil, cycloguanil, and pyrimethamine 
were extensively adopted as a replacing drug 
for chlroquine and even as a malaria-
preventing drug in regions where both P. fal-
ciparum and P. vivax existed. Nevertheless, 
several cases of failure in treatment of and/or 
prevention from vivax malaria have been re-
ported. This convinced many malariologists 
that the parasite is inherently resistant to anti-
folate drugs (18). However, further investiga-
tions proved the opposite (19). Authors have 
considered resistance of P. vivax to fansidar to 
be caused by inherent resistance of the para-
site to this drug whereas the mechanisms un-
derlying the resistance include point mutations 
in Pvdhfr and Pvdhps genes (6, 11, 20, 21). Sul-
fadoxine-pyrimethamine (known as fansidar) 
is not commonly prescribed to treat infections 
caused by P. vivax while treatment with fan-
sidar might be considered because the infec-
tion usually occurs concurrently with P. falcipa-
rum and is difficult to diagnose it very well (20-
22).  
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In the present study, a limited polymor-
phism in Pvdhps gene was found that was in 
contrast to earlier investigations in PNG (23) 
and Thailand (24).The wild-type Pvdhps is pre-
sent at high proportion in P. vivax parasite 
populations from Hormozgan Province, 
which was similar to that acquired from malar-
ia endemic regions in Iran and Pakistan (25, 
26). 
Although no relationship was seen between 
mutations in five main codons and resistance 
to sulfadoxine in the studied areas, it can be 
claimed that resistance of P. vivax to fansidar 
in Hormozgan may be occurring because mu-
tation at new codon 421 was detected and iso-
lates with double-mutations in Pvdhfr gene 
were found at codons 58 and 117 in these iso-
lates in Hormozgan Province (16) leading to 
resistance to pyrimethamine. 
 
Conclusion 
 
In spite of a high level of possibility of re-
sistance to pyrimethamine in south of Iran, 
fansidar may still be adopted owing to concur-
rent use with sulfadoxine which leads to its 
higher effect, unless resistance to sulfadoxine 
continues to lead its ever-increasing trend. 
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